

4. **Sagalovich D, Say R, Kaouk J, Mehrazin R.** The role of extended venous thromboembolism prophylaxis following urologic pelvic surgery. *Urol Oncol.* 2018; 36(3): 83–87.
5. **Tikkanen KAO, Craigie S, Agarwal A, et al.** Procedure-specific risks of thrombosis and bleeding in urological cancer surgery: systematic review and meta-analysis. *Eur Urol.* 2018; 73: 242–251.
6. **Tikkanen KAO, Craigie S, Agarwal A, et al.** Procedure-specific risks of thrombosis and bleeding in urological non-cancer surgery: systematic review and meta-analysis. *Eur Urol.* 2018; 73: 236–241.
7. **Violette PD, Cartwright R, Briel M, Tikkinen KAO, Guyatt GH.** Guideline of guidelines: thromboprophylaxis for urological surgery. *BJU Int.* 2016; 118: 351–358.
8. **Tikkanen KAO, Cartwright R, Gould MK, et al.** EAU guidelines on thromboprophylaxis in urological surgery. EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01-1.
9. **Gumulec J, Zänger M, Procházka V, Urbanec R, Klement P.** Prevence žilního tromboembolizmu v chirurgii, laparoskopické chirurgii, urologii. *Vnitř Léč.* 2009; 55(3): 196–203.
10. **Jordan BJ, Matulewicz RS, Trihn B, Kundu S.** Venous thromboembolism after nephrectomy: incidence, timing and associated risk factors from a national multi-institutional database. *World J Urol.* 2017; 35: 1713–1719.
11. **Klaassen Z, Arora K, Goldberg H, et al.** Extended venous thromboembolism prophylaxis after radical cystectomy: a call for adherence to current guidelines. *J Urol.* 2017; 197(2): 302–307.
12. **McAlpine K, Breau RH, Mallick R, et al.** Current guidelines do not sufficiently discriminate venous thromboembolism risk in urology. *Urol Oncol.* 2017; 35: 457. e1-457.e8.
13. **Chen EC, Papa N, Lawrentschuk N, Bolton D, Sengupta S.** Incidence and risk factors of venous thromboembolism after pelvic uro-oncologic surgery – a single center experience. *BJU Int.* 2016; 117 (Suppl 4): 50–53.
14. **Heinc P, Táborský M, Kováčik F, Lazárová M, Přeček J.** Perioperační riziko v éře nových antikoagulancií. *Urol. Praxi* 2013; 14(2): 77–80.
15. **Musil D, Študent V.** Prevence a léčba tromboembolické nemoci v urologii. *Urol. Praxi.* 2003; 1: 14–18.
16. **Ellis G, Camm JA, Datta SN.** Novel anticoagulants and antiplatelet agents; a guide for the urologist. *BJU Int.* 2015; 116: 687–696.
17. **Browne E, Haroon U, Davis NF, Forde JC.** Perioperative management of new oral anticoagulants in urological surgery. *Curr Urol.* 2017; 11: 169–174.
18. **Mottet N, Bergh RCN, Briers E, et al.** EAU guidelines on prostate cancer. EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01-1.
19. **Sahin C, Can U, Eryildirim B, Sarica K.** Transient cessation of antiplatelet medication before percutaneous stone surgery: does it have any safety concern on bleeding related problems? *Urolithiasis.* 2017; 45: 371–378.
20. **Valgimigli M, Bueno H, Byrne RA, et al.** 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J.* 2018; 39(3): 213–260.
21. **Bashar A, Kautzner J.** Perioperační péče o pacienty užívající antikoagulancia. *Interv Akut Kardiol.* 2017; 16(1): 18–22.
22. **Devereaux, PJ, Mrkobrada M, Sessler DI, et al.** Aspirin in patients undergoing noncardiac surgery. *N Engl J Med.* 2014; 370: 1494–1503.
23. **Gumulec J.** Hematologie na JIP/ARO, management antikoagulační prevence v krizových situacích. *Transfuzie a hematologie dnes.* 2018: 124–132. ISSN 1213–5763.
24. **Levy JH, Ageno W, Chan NC, et al.** When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. *J Thromb Haemost.* 2016; 14: 623–627.